Abstract

Abstract Introduction:The aim of this study was to investigate the association of donor myeloid-derived suppressor cells (MDSCs) in allografts with acute graft-versus host disease(aGVHD) in patients who had undergone granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood progenitor cell (G-PBPC) and G-CSF-primed bone marrow (G-BM) transplantation. Methods: Unmanipulated allografts from 71 patients were prospectively analyzed for MDSCs with respect to aGVHD, in which 23 patients got HLA-matched donors and 48 patients had haploidentical donors. Results: Median numbers (range) of monocytic/ granulocytic/ promyelocytic MDSCs were:3.43(0.31-10.65)×106/kg, 8.23(0.85-16.2 )×106/kg , 1.11(0.51-3.53)×107/kg ,respectively in G-BM and these of monocytic/ granulocytic MDSCs were:1.64(0.28-4.3)×107/kg , 1.96(0.62-6.2)×107/kg , respectively in G-PBPC. The incidence of grades II-IV aGVHD was 29.6%, and there was no difference between the HLA-matched and haploidentical transplantation group. Patients who received a higher dose of promyelocytic MDSCs(>0.82×107/kg, p<0.001) in G-BM or a higher total dose of monocytic MDSCs in G-BM and G-PBPC (>1.23×107/kg, p<0.001) exhibited a lower incidence of grades II-IV aGVHD. Conclusion: Our results suggest that a high number of MDSCs infused were associated with decreased risk of aGVHD in allogeneic blood and marrow transplantation, which may reflect the immune suppressive function of MDSCs in allogeneic transplantation.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.